

## Accomplishments

### Mayilvahanan Bose

My primary research focus is on identification of biomarkers for early diagnosis and therapeutic target in cervical cancer. Developed a Double antibody sandwich ELISA for p16 which would help screen women for cervical dysplasia and cancer. A patent has been filed and this technology is now transferred to HLL Lifecare Limited, (A Government of India Enterprise). Also as a member of large bowel microbiome disease network - we have been investigating the colorectal “microbiome” under collaboration with University of Leeds, UK.

### Key Publications:

1. Rajkumar T, Sabitha K, Vijayalakshmi N, Shirley S, **Bose MV**, Gopal G, et al. Identification and validation of genes involved in cervical tumourigenesis. *BMC Cancer*. 2011;11(1):80.
2. **Bose MV**, Gopal G, Selvaluxmy G, Rajkumar T. Dominant negative Ubiquitin-conjugating enzyme E2C sensitizes cervical cancer cells to radiation. *International Journal of Radiation Biology*. 2012;88(9):629–34.
3. **Bose MV**, Rajkumar T. Assessment of the Radiation Sensitivity of Cervical Cancer Cell Lines. In: Keppler D, Lin AW, editors. *Cervical Cancer*. New York, NY: Springer New York; 2015. p. 351–62.
4. Ammothumkandy A, Maliekal TT, **Bose MV**, Rajkumar T, Shirley S, Thejaswini B, et al. CD66 and CD49f expressing cells are associated with distinct neoplastic phenotypes and progression in human cervical cancer. *European Journal of Cancer*. 2016; 60:166–78.
5. Young C, Wood HM, Seshadri RA, Van Nang P, Vaccaro C, Melendez LC, et al. The colorectal cancer-associated faecal microbiome of developing countries resembles that of developed countries. *Genome Med*. 2021; 13(1):27.

Google scholar link: <https://scholar.google.com/citations?user=e5dJaskAAAAJ&hl=en>